Drug utilization study of cyproterone/ethinylestradiol (Diane®-35 and generics) in the Netherlands, UK and Italy

First published: 23/01/2015

Last updated: 02/07/2024

Study Finalised

Administrative details

EU PAS number

EUPAS8412

Study ID

31117

DARWIN EU® study

No

Study countries

- ☐ Italy
- ☐ Netherlands
- ☐ Spain

Study description

The study objectives are to characterize new users of Cyproterone Acetate / Ethinylestradiol (CPA/EE) in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in Healthcare Databases in the UK (THIN), the Netherlands (PHARMO) and Italy (HSD).

Study status

Finalised

Research institutions and networks

Institutions

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

Netherlands

First published: 07/01/2022

Last updated: 24/07/2024

Institution | **Laboratory/Research/Testing facility** | **ENCePP partner**

Fundación Centro Español de Investigación Farmacoepidemiológica (CEIFE)

Spain

First published: 15/03/2010

Last updated: 15/02/2024

Institution | Not-for-profit | ENCePP partner

Italy HIS: The Health Search institute

Networks

PHARMO: Database Network Netherlands

Contact details

Study institution contact

CTP Team / Ref: "ENCePP"/ Bayer Pharma AG Bayer HealthCare AG clinical-trials-contact@bayerhealthcare.com

Study contact

clinical-trials-contact@bayerhealthcare.com

Primary lead investigator

CTP Team / Ref: "ENCePP"/ Bayer Pharma AG Bayer HealthCare AG

Primary lead investigator

Study timelines

Date when funding contract was signed
Actual: 01/12/2014

Study start date
Planned: 01/02/2015

Actual: 01/05/2015

Date of final study report
Planned: 30/01/2016

Actual: 31/03/2016

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Bayer

Study protocol

17660_Study Protocol DUS Diane_2014-09-12.pdf(523.32 KB)

17660_02_Protocol_V7.0_2017_extension study.pdf(3.21 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 1 (imposed as condition of marketing authorisation)

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary use of data

Main study objective:

Characterization of new users of Cyproterone Acetate / Ethinylestradiol CPA/EE in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic

conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in Healthcare Databases in the UK (THIN), the NL (PHARMO) and Italy (HSD).

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(G03HB) Antiandrogens and estrogens

Antiandrogens and estrogens

Population studied

Short description of the study population

New Cyproterone Acetate / Ethinylestradiol (CPA/EE) users in 2011 and 2012.

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Estimated number of subjects

10000

Study design details

Outcomes

1. Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Acne2. Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Hirsutism3. Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of other Hyperandrogenic Conditions (e.g. androgenic alopecia, seborrhea, polycystic ovary syndrome), 1. Determination of previous acne treatments (prescription drugs only) of Diane-35 (or generics) users with a previous diagnosis of acne.2. Proportion (%) of new Diane-35 (or generics) users, who have concomitant prescriptions of other combined oral contraceptives

---

Data analysis plan

Patient, treatment and diagnosis characteristics will be reported descriptively. Categorical data will be presented as counts (n) and proportions (%). Continuous data will be presented as means with standard deviation (SD) and as medians with inter quartile range (IQR) when appropriate. Results will be presented for the 2011/2012 users together and stratified by year of diagnosis.

Documents

Study results

17660_EU-PAS_Abstract.pdf(59.26 KB)

17660_Study Report DUS Diane - final.pdf(727.15 KB)

Study report

17660_04_Report.pdf(2.12 MB)

17660_04_Report extension.pdf(4.03 MB)

17660_04_Report_ 1_interim.pdf(727.05 KB)

Study, other information

17660_04_Report.pdf(2.12 MB)

17660_04_Report_ 1_interim.pdf(727.05 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

THIN® (The Health Improvement Network®)

PHARMO Data Network

Data source(s), other

HSD Italy

Data sources (types)

Administrative healthcare records (e.g., claims)

Drug dispensing/prescription data

Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No